Clinical Trials Logo

Prodromal Schizophrenia clinical trials

View clinical trials related to Prodromal Schizophrenia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05877716 Recruiting - Schizophrenia Clinical Trials

EPI-MINN: Targeting Cognition and Motivation - National

Start date: May 30, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to perform a practice-based research project designed to assess whether cognition and motivated behavior in early psychosis can be addressed as key treatment goals within real-world settings by using a 12-week mobile intervention program. Participants who are receiving care at coordinated specialty care (CSC) early psychosis clinics across the United States will be recruited to participate in this study. A qualifying CSC program will provide comprehensive clinical services such as psychotherapy, medication management, psychoeducation, and work or education support. This study will be conducted remotely, and participants can participate at home with their own electronic devices. The aim of this study is to investigate a well-defined 12-week mobile intervention program specifically designed to target cognitive functioning and motivated behavior for individuals with early psychosis. Participants will complete a screening interview which will include diagnosis and symptom ratings, neurocognitive assessment, and self-reports of symptoms, behavior, and functioning. Then participants will be randomized to receive the 12-week mobile intervention, or an active control of treatment as usual. The investigators will test for differences in the clinical trajectories after training, and at two follow up appointments at 6 and 12 months post-training.

NCT ID: NCT05167396 Recruiting - Healthy Controls Clinical Trials

REtinal and VIsual Cortical Response in Early PSYchosis

REVIPSY
Start date: January 26, 2022
Phase: N/A
Study type: Interventional

The purpose of the REVIPSY study is to measure retinal and the visual cortical electrophysiological responses in situations at risk of psychosis in patients who have experienced a first psychotic episode. A perspective of this project will be to create new electrophysiological biomarkers predictive of the risk of conversion to psychosis

NCT ID: NCT05142735 Recruiting - Clinical trials for Prodromal Schizophrenia

Effects of NAC on Symptoms of CHR Patients

Start date: January 13, 2023
Phase: N/A
Study type: Interventional

Schizophrenia is a chronic debilitating psychotic disorder. Identifying persons with "clinical high-risk" (CHR) symptoms, which are like those of schizophrenia but less severe, and providing psychiatric care to these individuals has been shown to help prevent psychosis. Current medications used for CHR symptoms, however, are associated with substantial side effect burden. Therefore, practice guidelines do not recommend current medications as routine treatment for the CHR state, and there is a need to identify new treatments for this condition. Research suggests that abnormal brain oxidative stress may contribute to schizophrenia, offering a potential novel treatment target in the CHR state. Oxidative stress is an excess of free radicals, which are generated from normal metabolism and environmental exposures, and can damage cells. Antioxidants in the body normally neutralize free radicals. Antioxidant deficiency could result in excess oxidative stress that damages brain cells, leading to schizophrenia. Recent studies suggest that N-acetylcysteine (NAC), a precursor of the most abundant brain antioxidant, glutathione, may be a safe, well-tolerated treatment for schizophrenia. In light of this, NAC may also reduce symptoms and brain abnormalities in CHR patients.

NCT ID: NCT05131035 Recruiting - Psychosis Clinical Trials

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk

SCORES
Start date: October 28, 2021
Phase: N/A
Study type: Interventional

This 10 week intervention, Specific Cognitive Remediation with Surround (or SCORES), is designed to target processing speed, a cognitive domain related directly to social functioning, which in turn, represents a vulnerability factor for psychosis. This remotely-delivered intervention combining targeted cognitive training exercises and group support was developed to directly impact processing speed, and at the same time, boost motivation and engagement in adolescents at risk for schizophrenia and other psychotic disorders.

NCT ID: NCT05052853 Recruiting - Clinical trials for Prodromal Schizophrenia

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

Start date: November 1, 2021
Phase: Phase 2
Study type: Interventional

Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia deserves study.

NCT ID: NCT04338152 Recruiting - Psychosis Clinical Trials

Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial

Start date: January 15, 2021
Phase: N/A
Study type: Interventional

The present study is a confirmatory efficacy trial of Family Focused Therapy for youth at clinical high risk for psychosis (FFT-CHR). This trial is sponsored by seven mature CHR clinical research programs from the North American Prodrome Longitudinal Study (NAPLS). The young clinical high risk sample (N = 220 youth ages 13-25) is to be followed at 6-month intervals for 18 months.

NCT ID: NCT03751865 Recruiting - Clinical trials for Prodromal Schizophrenia

Early Detection and Intervention for Women At-risk of Psychosis

Start date: November 15, 2018
Phase: N/A
Study type: Interventional

This study aims to examine the effectiveness of the cognitive behavioral therapy in preventing the conversion of psychosis in a sample of individuals at-risk for psychosis.